National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts.org
Search Results

This is VAERS ID 631159

Government Disclaimer on use of this data

History of Changes from the VAERS Wayback Machine

First Appeared on 5/14/2016

VAERS ID: 631159
VAERS Form:
Age:16.0
Sex:Female
Location:Unknown
Vaccinated:2016-02-27
Onset:2016-02-28
Submitted:2016-04-09
Entered:2016-04-12
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / 1 UN / UN
MENB: MENINGOCOCCAL B (BEXSERO) / NOVARTIS VACCINES AND DIAGNOSTICS L045711 / 0 UN / UN

Administered by: Other      Purchased by: Other
Symptoms: Swelling face

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': US2016044229

Write-up: This case was reported by a other health professional via call center representative and described the occurrence of facial swelling in a 16-year-old female patient who received BEXSERO (batch number L045711, expiry date 8th May 2017). Concomitant products included GARDASIL. On 27th February 2016, the patient received 1st dose of BEXSERO. In February 2016, 1 day after receiving BEXSERO, the patient experienced facial swelling. On 5th March 2016, the outcome of the facial swelling was recovered/resolved. It was unknown if the reporter considered the facial swelling to be related to BEXSERO. Additional details provided were as follows: The patient had received GARDASIL previously with no adverse reactions. The patient experienced face swelling which lasted for 1 week and which was described as severe, uncomfortable, and embarrassing. There were no other associated symptoms.


Changed on 9/14/2017

VAERS ID: 631159 Before After
VAERS Form:(blank) 1
Age:16.0
Sex:Female
Location:Unknown
Vaccinated:2016-02-27
Onset:2016-02-28
Submitted:2016-04-09
Entered:2016-04-12
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / 1 2 UN / UN
MENB: MENINGOCOCCAL B (BEXSERO) / NOVARTIS VACCINES AND DIAGNOSTICS L045711 / 0 1 UN / UN

Administered by: Other      Purchased by: Other
Symptoms: Swelling face

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': US2016044229

Write-up: This case was reported by a other health professional via call center representative and described the occurrence of facial swelling in a 16-year-old female patient who received BEXSERO (batch number L045711, expiry date 8th May 2017). Concomitant products included GARDASIL. On 27th February 2016, the patient received 1st dose of BEXSERO. In February 2016, 1 day after receiving BEXSERO, the patient experienced facial swelling. On 5th March 2016, the outcome of the facial swelling was recovered/resolved. It was unknown if the reporter considered the facial swelling to be related to BEXSERO. Additional details provided were as follows: The patient had received GARDASIL previously with no adverse reactions. The patient experienced face swelling which lasted for 1 week and which was described as severe, uncomfortable, and embarrassing. There were no other associated symptoms.


Changed on 2/14/2018

VAERS ID: 631159 Before After
VAERS Form:1
Age:16.0
Sex:Female
Location:Unknown
Vaccinated:2016-02-27
Onset:2016-02-28
Submitted:2016-04-09
Entered:2016-04-12
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / 2 UN / UN
MENB: MENINGOCOCCAL B (BEXSERO) / NOVARTIS VACCINES AND DIAGNOSTICS L045711 / 1 UN / UN

Administered by: Other      Purchased by: Other
Symptoms: Swelling face

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': US2016044229

Write-up: This case was reported by a other health professional via call center representative and described the occurrence of facial swelling in a 16-year-old female patient who received BEXSERO (batch number L045711, expiry date 8th May 2017). Concomitant products included GARDASIL. On 27th February 2016, the patient received 1st dose of BEXSERO. In February 2016, 1 day after receiving BEXSERO, the patient experienced facial swelling. On 5th March 2016, the outcome of the facial swelling was recovered/resolved. It was unknown if the reporter considered the facial swelling to be related to BEXSERO. Additional details provided were as follows: The patient had received GARDASIL previously with no adverse reactions. The patient experienced face swelling which lasted for 1 week and which was described as severe, uncomfortable, and embarrassing. There were no other associated symptoms.


Changed on 6/14/2018

VAERS ID: 631159 Before After
VAERS Form:1
Age:16.0
Sex:Female
Location:Unknown
Vaccinated:2016-02-27
Onset:2016-02-28
Submitted:2016-04-09
Entered:2016-04-12
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / 2 UN / UN
MENB: MENINGOCOCCAL B (BEXSERO) / NOVARTIS VACCINES AND DIAGNOSTICS L045711 / 1 UN / UN

Administered by: Other      Purchased by: Other
Symptoms: Swelling face

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': US2016044229

Write-up: This case was reported by a other health professional via call center representative and described the occurrence of facial swelling in a 16-year-old female patient who received BEXSERO (batch number L045711, expiry date 8th May 2017). Concomitant products included GARDASIL. On 27th February 2016, the patient received 1st dose of BEXSERO. In February 2016, 1 day after receiving BEXSERO, the patient experienced facial swelling. On 5th March 2016, the outcome of the facial swelling was recovered/resolved. It was unknown if the reporter considered the facial swelling to be related to BEXSERO. Additional details provided were as follows: The patient had received GARDASIL previously with no adverse reactions. The patient experienced face swelling which lasted for 1 week and which was described as severe, uncomfortable, and embarrassing. There were no other associated symptoms.


Changed on 8/14/2018

VAERS ID: 631159 Before After
VAERS Form:1
Age:16.0
Sex:Female
Location:Unknown
Vaccinated:2016-02-27
Onset:2016-02-28
Submitted:2016-04-09
Entered:2016-04-12
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / 2 UN / UN
MENB: MENINGOCOCCAL B (BEXSERO) / NOVARTIS VACCINES AND DIAGNOSTICS L045711 / 1 UN / UN

Administered by: Other      Purchased by: Other
Symptoms: Swelling face

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': US2016044229

Write-up: This case was reported by a other health professional via call center representative and described the occurrence of facial swelling in a 16-year-old female patient who received BEXSERO (batch number L045711, expiry date 8th May 2017). Concomitant products included GARDASIL. On 27th February 2016, the patient received 1st dose of BEXSERO. In February 2016, 1 day after receiving BEXSERO, the patient experienced facial swelling. On 5th March 2016, the outcome of the facial swelling was recovered/resolved. It was unknown if the reporter considered the facial swelling to be related to BEXSERO. Additional details provided were as follows: The patient had received GARDASIL previously with no adverse reactions. The patient experienced face swelling which lasted for 1 week and which was described as severe, uncomfortable, and embarrassing. There were no other associated symptoms.


Changed on 9/14/2018

VAERS ID: 631159 Before After
VAERS Form:1
Age:16.0
Sex:Female
Location:Unknown
Vaccinated:2016-02-27
Onset:2016-02-28
Submitted:2016-04-09
Entered:2016-04-12
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / 2 UN / UN
MENB: MENINGOCOCCAL B (BEXSERO) / NOVARTIS VACCINES AND DIAGNOSTICS L045711 / 1 UN / UN

Administered by: Other      Purchased by: Other
Symptoms: Swelling face

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': US2016044229

Write-up: This case was reported by a other health professional via call center representative and described the occurrence of facial swelling in a 16-year-old female patient who received BEXSERO (batch number L045711, expiry date 8th May 2017). Concomitant products included GARDASIL. On 27th February 2016, the patient received 1st dose of BEXSERO. In February 2016, 1 day after receiving BEXSERO, the patient experienced facial swelling. On 5th March 2016, the outcome of the facial swelling was recovered/resolved. It was unknown if the reporter considered the facial swelling to be related to BEXSERO. Additional details provided were as follows: The patient had received GARDASIL previously with no adverse reactions. The patient experienced face swelling which lasted for 1 week and which was described as severe, uncomfortable, and embarrassing. There were no other associated symptoms.


Changed on 10/14/2018

VAERS ID: 631159 Before After
VAERS Form:1
Age:16.0
Sex:Female
Location:Unknown
Vaccinated:2016-02-27
Onset:2016-02-28
Submitted:2016-04-09
Entered:2016-04-12
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / 2 UN / UN
MENB: MENINGOCOCCAL B (BEXSERO) / NOVARTIS VACCINES AND DIAGNOSTICS L045711 / 1 UN / UN

Administered by: Other      Purchased by: Other
Symptoms: Swelling face

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': US2016044229

Write-up: This case was reported by a other health professional via call center representative and described the occurrence of facial swelling in a 16-year-old female patient who received BEXSERO (batch number L045711, expiry date 8th May 2017). Concomitant products included GARDASIL. On 27th February 2016, the patient received 1st dose of BEXSERO. In February 2016, 1 day after receiving BEXSERO, the patient experienced facial swelling. On 5th March 2016, the outcome of the facial swelling was recovered/resolved. It was unknown if the reporter considered the facial swelling to be related to BEXSERO. Additional details provided were as follows: The patient had received GARDASIL previously with no adverse reactions. The patient experienced face swelling which lasted for 1 week and which was described as severe, uncomfortable, and embarrassing. There were no other associated symptoms.


Changed on 4/14/2019

VAERS ID: 631159 Before After
VAERS Form:1
Age:16.0
Sex:Female
Location:Unknown
Vaccinated:2016-02-27
Onset:2016-02-28
Submitted:2016-04-09
Entered:2016-04-12
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / 2 UN / UN
MENB: MENINGOCOCCAL B (BEXSERO) / NOVARTIS VACCINES AND DIAGNOSTICS L045711 / 1 UN RA / UN IM

Administered by: Other      Purchased by: Other
Symptoms: Swelling face

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': US2016044229

Write-up: This case was reported by a other health professional via call center representative and described the occurrence of facial swelling in a 16-year-old female patient who received BEXSERO (batch number L045711, expiry date 8th May 2017). Concomitant products included GARDASIL. On 27th February 2016, the patient received 1st dose of BEXSERO. In February 2016, 1 day after receiving BEXSERO, the patient experienced facial swelling. On 5th March 2016, the outcome of the facial swelling was recovered/resolved. It was unknown if the reporter considered the facial swelling to be related to BEXSERO. Additional details provided were as follows: The patient had received GARDASIL previously with no adverse reactions. The patient experienced face swelling which lasted for 1 week and which was described as severe, uncomfortable, and embarrassing. There were no other associated symptoms.


Changed on 12/10/2020

VAERS ID: 631159 Before After
VAERS Form:1
Age:16.0
Sex:Female
Location:Unknown New York
Vaccinated:2016-02-27
Onset:2016-02-28
Submitted:2016-04-09
Entered:2016-04-12
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / 2 UN / UN
MENB: MENINGOCOCCAL B (BEXSERO) / NOVARTIS VACCINES AND DIAGNOSTICS L045711 / 1 RA / IM

Administered by: Other      Purchased by: Other
Symptoms: Swelling face

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': US2016044229

Write-up: This case was reported by a other health professional via call center representative and described the occurrence of facial swelling in a 16-year-old female patient who received BEXSERO (batch number L045711, expiry date 8th May 2017). Concomitant products included GARDASIL. On 27th February 2016, the patient received 1st dose of BEXSERO. In February 2016, 1 day after receiving BEXSERO, the patient experienced facial swelling. On 5th March 2016, the outcome of the facial swelling was recovered/resolved. It was unknown if the reporter considered the facial swelling to be related to BEXSERO. Additional details provided were as follows: The patient had received GARDASIL previously with no adverse reactions. The patient experienced face swelling which lasted for 1 week and which was described as severe, uncomfortable, and embarrassing. There were no other associated symptoms.


Changed on 12/24/2020

VAERS ID: 631159 Before After
VAERS Form:1
Age:16.0
Sex:Female
Location:New York
Vaccinated:2016-02-27
Onset:2016-02-28
Submitted:2016-04-09
Entered:2016-04-12
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / 2 UN / UN
MENB: MENINGOCOCCAL B (BEXSERO) / NOVARTIS VACCINES AND DIAGNOSTICS L045711 / 1 RA / IM

Administered by: Other      Purchased by: Other
Symptoms: Swelling face

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': US2016044229

Write-up: This case was reported by a other health professional via call center representative and described the occurrence of facial swelling in a 16-year-old female patient who received BEXSERO (batch number L045711, expiry date 8th May 2017). Concomitant products included GARDASIL. On 27th February 2016, the patient received 1st dose of BEXSERO. In February 2016, 1 day after receiving BEXSERO, the patient experienced facial swelling. On 5th March 2016, the outcome of the facial swelling was recovered/resolved. It was unknown if the reporter considered the facial swelling to be related to BEXSERO. Additional details provided were as follows: The patient had received GARDASIL previously with no adverse reactions. The patient experienced face swelling which lasted for 1 week and which was described as severe, uncomfortable, and embarrassing. There were no other associated symptoms.


Changed on 12/30/2020

VAERS ID: 631159 Before After
VAERS Form:1
Age:16.0
Sex:Female
Location:New York
Vaccinated:2016-02-27
Onset:2016-02-28
Submitted:2016-04-09
Entered:2016-04-12
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / 2 UN / UN
MENB: MENINGOCOCCAL B (BEXSERO) / NOVARTIS VACCINES AND DIAGNOSTICS L045711 / 1 RA / IM

Administered by: Other      Purchased by: Other
Symptoms: Swelling face

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': US2016044229

Write-up: This case was reported by a other health professional via call center representative and described the occurrence of facial swelling in a 16-year-old female patient who received BEXSERO (batch number L045711, expiry date 8th May 2017). Concomitant products included GARDASIL. On 27th February 2016, the patient received 1st dose of BEXSERO. In February 2016, 1 day after receiving BEXSERO, the patient experienced facial swelling. On 5th March 2016, the outcome of the facial swelling was recovered/resolved. It was unknown if the reporter considered the facial swelling to be related to BEXSERO. Additional details provided were as follows: The patient had received GARDASIL previously with no adverse reactions. The patient experienced face swelling which lasted for 1 week and which was described as severe, uncomfortable, and embarrassing. There were no other associated symptoms.


Changed on 5/7/2021

VAERS ID: 631159 Before After
VAERS Form:1
Age:16.0
Sex:Female
Location:New York
Vaccinated:2016-02-27
Onset:2016-02-28
Submitted:2016-04-09
Entered:2016-04-12
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / 2 UN / UN
MENB: MENINGOCOCCAL B (BEXSERO) / NOVARTIS VACCINES AND DIAGNOSTICS L045711 / 1 RA / IM

Administered by: Other      Purchased by: Other
Symptoms: Swelling face

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': US2016044229

Write-up: This case was reported by a other health professional via call center representative and described the occurrence of facial swelling in a 16-year-old female patient who received BEXSERO (batch number L045711, expiry date 8th May 2017). Concomitant products included GARDASIL. On 27th February 2016, the patient received 1st dose of BEXSERO. In February 2016, 1 day after receiving BEXSERO, the patient experienced facial swelling. On 5th March 2016, the outcome of the facial swelling was recovered/resolved. It was unknown if the reporter considered the facial swelling to be related to BEXSERO. Additional details provided were as follows: The patient had received GARDASIL previously with no adverse reactions. The patient experienced face swelling which lasted for 1 week and which was described as severe, uncomfortable, and embarrassing. There were no other associated symptoms.


Changed on 5/21/2021

VAERS ID: 631159 Before After
VAERS Form:1
Age:16.0
Sex:Female
Location:New York
Vaccinated:2016-02-27
Onset:2016-02-28
Submitted:2016-04-09
Entered:2016-04-12
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / 2 UN / UN
MENB: MENINGOCOCCAL B (BEXSERO) / NOVARTIS VACCINES AND DIAGNOSTICS L045711 / 1 RA / IM

Administered by: Other      Purchased by: Other
Symptoms: Swelling face

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': US2016044229

Write-up: This case was reported by a other health professional via call center representative and described the occurrence of facial swelling in a 16-year-old female patient who received BEXSERO (batch number L045711, expiry date 8th May 2017). Concomitant products included GARDASIL. On 27th February 2016, the patient received 1st dose of BEXSERO. In February 2016, 1 day after receiving BEXSERO, the patient experienced facial swelling. On 5th March 2016, the outcome of the facial swelling was recovered/resolved. It was unknown if the reporter considered the facial swelling to be related to BEXSERO. Additional details provided were as follows: The patient had received GARDASIL previously with no adverse reactions. The patient experienced face swelling which lasted for 1 week and which was described as severe, uncomfortable, and embarrassing. There were no other associated symptoms.

New Search

Link To This Search Result:

https://www.medalerts.org/vaersdb/findfield.php?IDNUMBER=631159&WAYBACKHISTORY=ON


Copyright © 2022 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166